Literature DB >> 20697043

Frequency and prognosis of convulsive status epilepticus of different causes: a systematic review.

Aidan Neligan1, Simon D Shorvon.   

Abstract

We conducted a systematic review of all studies of status epilepticus (SE) with more than 30 patients published between January 1, 1990, and December 31, 2008, to determine the frequencies of the common underlying causes and the extent to which the underlying causes affect the prognosis of an episode of SE. The frequencies of underlying causes vary among studies and show marked geographic differences, but in most studies, the most common underlying causes were cerebrovascular disease and low antiepileptic drug levels. A relatively good prognosis of SE is found when the underlying cause is associated with low antiepileptic drug levels or alcohol abuse, and a relatively poor outcome occurs when the underlying cause is cerebrovascular disease, particularly in the case of SE due to acute cerebral anoxia, but in most conditions, the reported prognosis is variable. Also, when SE occurs in the context of an acute cerebral insult, such as cerebral infection or cerebrovascular disease, the prognosis of the acute cerebral event is worsened.

Entities:  

Mesh:

Year:  2010        PMID: 20697043     DOI: 10.1001/archneurol.2010.169

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  39 in total

1.  What is specialized care in status epilepticus and in which ICU?

Authors:  Sophie Demeret; Nicolas Weiss; Francis Bolgert; Vincent Navarro
Journal:  Neurocrit Care       Date:  2013-08       Impact factor: 3.210

2.  Non-convulsive status epilepticus in brain tumors.

Authors:  M Casazza; I Gilioli
Journal:  Neurol Sci       Date:  2011-11       Impact factor: 3.307

3.  Evaluation of STESS, mRSTESS, and EMSE to Predict High Disability and Mortality at Hospital Discharge in Ecuadorian Patients with Status Epilepticus.

Authors:  Dannys Rivero Rodríguez; Claudio Scherle Matamoros; Kimberly Sam; Daniela DiCapua Sacoto; Nelson Maldonado Samaniego; Yanelis Pernas
Journal:  Neurocrit Care       Date:  2018-12       Impact factor: 3.210

Review 4.  Pharmacotherapy for Refractory and Super-Refractory Status Epilepticus in Adults.

Authors:  Martin Holtkamp
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

5.  The established status epilepticus trial 2013.

Authors:  Thomas Bleck; Hannah Cock; James Chamberlain; James Cloyd; Jason Connor; Jordan Elm; Nathan Fountain; Elizabeth Jones; Daniel Lowenstein; Shlomo Shinnar; Robert Silbergleit; David Treiman; Eugen Trinka; Jaideep Kapur
Journal:  Epilepsia       Date:  2013-09       Impact factor: 5.864

6.  HMGB1 Is a Therapeutic Target and Biomarker in Diazepam-Refractory Status Epilepticus with Wide Time Window.

Authors:  Junli Zhao; Yang Zheng; Keyue Liu; Junzi Chen; Nanxi Lai; Fan Fei; Jiaying Shi; Cenglin Xu; Shuang Wang; Masahiro Nishibori; Yi Wang; Zhong Chen
Journal:  Neurotherapeutics       Date:  2020-04       Impact factor: 7.620

7.  Epidemiology-based mortality score in status epilepticus (EMSE).

Authors:  M Leitinger; Y Höller; G Kalss; A Rohracher; H F Novak; J Höfler; J Dobesberger; G Kuchukhidze; E Trinka
Journal:  Neurocrit Care       Date:  2015-04       Impact factor: 3.210

8.  Somatostatin type-2 receptor activation inhibits glutamate release and prevents status epilepticus.

Authors:  Maxim Kozhemyakin; Karthik Rajasekaran; Marko S Todorovic; Samuel L Kowalski; Corinne Balint; Jaideep Kapur
Journal:  Neurobiol Dis       Date:  2013-03-05       Impact factor: 5.996

9.  α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptor Plasticity Sustains Severe, Fatal Status Epilepticus.

Authors:  Nadia Adotevi; Ewa Lewczuk; Huayu Sun; Suchitra Joshi; Natalia Dabrowska; Sarah Shan; John Williamson; Jaideep Kapur
Journal:  Ann Neurol       Date:  2019-11-20       Impact factor: 10.422

10.  Familial aggregation of status epilepticus in generalized and focal epilepsies.

Authors:  Judith L Z Weisenberg; Robert T Fitzgerald; John N Constantino; Melodie R Winawer; Liu Lin Thio
Journal:  Neurology       Date:  2020-09-11       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.